Foster Dykema Cabot & CO Inc Repligen Corp Transaction History
Foster Dykema Cabot & CO Inc
- $827 Million
- Q3 2023
Shares
1 transactions
Others Institutions Holding RGEN
# of Institutions
495Shares Held
57.6MCall Options Held
75.6KPut Options Held
521K-
Black Rock Inc. New York, NY7.57MShares$965 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.57MShares$964 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$648 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$215 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.67MShares$213 Million0.04% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.07B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....